Laboratory Corp. of America Stock Price, News & Analysis (NYSE:LH)

$174.39 1.28 (0.74 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$174.39
Today's Range$173.22 - $174.79
52-Week Range$128.00 - $174.79
Volume637,507 shs
Average Volume408,280 shs
Market Capitalization$17.62 billion
P/E Ratio18.61
Dividend YieldN/A
Beta0.87

About Laboratory Corp. of America (NYSE:LH)

Laboratory Corp. of America logoLaboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Healthcare Facilities & Services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:LH
CUSIP50540R40
Phone336-229-1127

Debt

Debt-to-Equity Ratio1.18%
Current Ratio1.89%
Quick Ratio1.75%

Price-To-Earnings

Trailing P/E Ratio18.61
Forward P/E Ratio18.30
P/E Growth1.65

Sales & Book Value

Annual Sales$9.64 billion
Price / Sales1.84
Cash Flow$13.91 per share
Price / Cash12.54
Book Value$53.45 per share
Price / Book3.26

Profitability

Trailing EPS$7.15
Net Income$732.10 million
Net Margins7.40%
Return on Equity16.75%
Return on Assets6.43%

Miscellaneous

Employees52,000
Outstanding Shares101,800,000

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) issued its earnings results on Wednesday, October, 25th. The medical research company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.38 by $0.08. The medical research company had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.55 billion. Laboratory Corp. of America had a return on equity of 16.75% and a net margin of 7.40%. Laboratory Corp. of America's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.25 earnings per share. View Laboratory Corp. of America's Earnings History.

When will Laboratory Corp. of America make its next earnings announcement?

Laboratory Corp. of America is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Laboratory Corp. of America.

Where is Laboratory Corp. of America's stock going? Where will Laboratory Corp. of America's stock price be in 2018?

13 Wall Street analysts have issued 12 month price objectives for Laboratory Corp. of America's shares. Their forecasts range from $146.00 to $195.00. On average, they anticipate Laboratory Corp. of America's stock price to reach $171.83 in the next year. View Analyst Ratings for Laboratory Corp. of America.

What are Wall Street analysts saying about Laboratory Corp. of America stock?

Here are some recent quotes from research analysts about Laboratory Corp. of America stock:

  • 1. According to Zacks Investment Research, "Over the past six months LabCorp has been trading above the broader industry. The company’s Diagnostics business continues to remain strong on improving price, mix, acquisition and favorable foreign exchange. Also after several quarters of dull show, Covance Drug Development reported strong growth on the back of the acquisition of Chiltern, strong organic growth and favorable foreign currency translation. An increased 2017 guidance boosts investors’ confidence indicating chances of this bullish trend to be maintained in the fourth quarter too. However, the current economic uncertainty including challenging volume environment for testing laboratories and utilization weaknesses are looming headwinds for LabCorp. Also, the company's revenue growth was constrained by the impact from multiple hurricanes during the last reported quarter." (1/10/2018)
  • 2. Canaccord Genuity analysts commented, "LH bounced back from an underwhelming Q3 with a good Q4 that beat our/consensus estimates on the top and bottom lines. The 2017 guide is what we expected and we believe sets an appropriate bar for the company to execute against. LH spent a good portion of time on its call (in the Q&A) defending its strategic planning and responded to questions about its reported interest (Reuters) to acquire NC-based CRO Pharmaceutical Product Development (PPD) for ~$8 billion. While on one hand the deal would make sense to bolster its Covance business, our sense from investors is that most would prefer to see LH return more of its capital to shareholders in the form of share repurchases, which LH re-initiated in Q4. Regardless, we think the stock is cheap and it remains one of our five top picks for 2017 as we expect "mean-reverted" multiple expansion and another solid year of FCF (~$975M, or $9.43/sh.) and strong capital deployment. BUY. We raise our estimates and PT to $150 from $140." (2/17/2017)
  • 3. Mizuho analysts commented, "We are raising our price target to $139 ($135 previously) post 4Q on betterthan-expected cash flow guidance. We are maintaining our 2017E and 2018E adjusted EPS estimates of $9.65 and $10.32, respectively. LH reported a good 4Q and initial 2017 guidance despite some noise. The company also noted a more conservative approach to its CRO metrics, which we view favorably." (2/17/2017)

Who are some of Laboratory Corp. of America's key competitors?

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the folowing people:

  • David P. King, Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Glenn A. Eisenberg, Chief Financial Officer, Executive Vice President (Age 55)
  • John D. Ratliff, Chief Executive Officer - Covance Drug Development (Age 57)
  • Lisa J. Uthgenannt, Chief Human Resource Officer (Age 56)
  • Edward T. Dodson, Senior Vice President, Chief Accounting Officer, Principal Accounting Officer (Age 63)
  • Lance V. Berberian, Senior Vice President, Chief Information Officer (Age 54)
  • F. Samuel Eberts III, Senior Vice President, Chief Compliance Officer, Secretary, Chief Legal Officer (Age 57)
  • Robert E. Mittelstaedt Jr., Lead Independent Director (Age 73)
  • Kerrii B. Anderson, Independent Director (Age 60)
  • Jean-Luc Belingard, Independent Director (Age 68)

Who owns Laboratory Corp. of America stock?

Laboratory Corp. of America's stock is owned by a number of of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.36%), Bank of Montreal Can (0.32%), AMI Asset Management Corp (0.24%), Country Trust Bank (0.14%), Bartlett & Co. LLC (0.14%) and National Pension Service (0.11%). Company insiders that own Laboratory Corp. of America stock include David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, James T Jr Boyle, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.

Who sold Laboratory Corp. of America stock? Who is selling Laboratory Corp. of America stock?

Laboratory Corp. of America's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, AMI Asset Management Corp, Contravisory Investment Management Inc., Country Trust Bank, Exxonmobil Investment Management Inc. TX, Catawba Capital Management VA, National Investment Services Inc. WI and Country Club Trust Company n.a.. Company insiders that have sold Laboratory Corp. of America company stock in the last year include David P King, Dwight Gary Gilliland, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt, R Sanders Williams and Robert E Mittelstaedt Jr. View Insider Buying and Selling for Laboratory Corp. of America.

Who bought Laboratory Corp. of America stock? Who is buying Laboratory Corp. of America stock?

Laboratory Corp. of America's stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Wasatch Advisors Inc., Franklin Street Advisors Inc. NC, State of Alaska Department of Revenue, Sheets Smith Wealth Management, Koshinski Asset Management Inc., National Pension Service and Sawyer & Company Inc. View Insider Buying and Selling for Laboratory Corp. of America.

How do I buy Laboratory Corp. of America stock?

Shares of Laboratory Corp. of America can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of Laboratory Corp. of America stock can currently be purchased for approximately $174.39.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $17.86 billion and generates $9.64 billion in revenue each year. The medical research company earns $732.10 million in net income (profit) each year or $7.17 on an earnings per share basis. Laboratory Corp. of America employs 52,000 workers across the globe.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 S MAIN ST, BURLINGTON, NC 27215-5837, United States. The medical research company can be reached via phone at +1-336-2291127 or via email at [email protected]


MarketBeat Community Rating for Laboratory Corp. of America (LH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  386 (Vote Underperform)
Total Votes:  712
MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Laboratory Corp. of America (NYSE:LH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.622.582.622.58
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $171.83$171.45$170.33$156.64
Price Target Upside: 5.39% upside9.89% upside12.27% upside1.92% upside

Laboratory Corp. of America (NYSE:LH) Consensus Price Target History

Price Target History for Laboratory Corp. of America (NYSE:LH)

Laboratory Corp. of America (NYSE:LH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018Evercore ISIInitiated CoverageOutperform -> Outperform$176.00HighView Rating Details
12/13/2017BarclaysReiterated RatingBuy$195.00LowView Rating Details
12/1/2017MizuhoSet Price TargetNeutral -> Neutral$160.00 -> $165.00MediumView Rating Details
11/24/2017Jefferies GroupSet Price TargetHold$167.00LowView Rating Details
10/27/2017Robert W. BairdReiterated RatingHold$150.00N/AView Rating Details
10/26/2017Deutsche BankBoost Price TargetBuy$170.00 -> $172.00N/AView Rating Details
10/26/2017Craig HallumReiterated RatingBuy$175.00 -> $180.00N/AView Rating Details
10/12/2017SunTrust BanksReiterated RatingBuy$190.00N/AView Rating Details
10/12/2017Wells Fargo & CoInitiated CoverageMarket Perform -> Outperform$175.00N/AView Rating Details
9/26/2017KeyCorpReiterated RatingHoldLowView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$175.00 -> $180.00MediumView Rating Details
8/10/2017Morgan StanleyBoost Price TargetOverweight$154.00 -> $166.00LowView Rating Details
7/13/2017Credit Suisse GroupDowngradeHold$146.00LowView Rating Details
10/25/2016GabelliInitiated CoverageBuy$180.00N/AView Rating Details
9/9/2016CitigroupInitiated CoverageNeutral$156.00N/AView Rating Details
3/23/2016Goldman Sachs GroupBoost Price Target$119.00N/AView Rating Details
3/4/2016William BlairReiterated RatingOutperformN/AView Rating Details
2/19/2016Royal Bank of CanadaLower Price TargetSector Perform$135.00 -> $130.00N/AView Rating Details
2/4/2016Raymond James FinancialLower Price TargetOutperform$145.00 -> $135.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Laboratory Corp. of America (NYSE:LH) Earnings History and Estimates Chart

Earnings by Quarter for Laboratory Corp. of America (NYSE:LH)

Laboratory Corp. of America (NYSE LH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018$2.38N/AView Earnings Details
2/6/2018$2.37N/AView Earnings Details
10/25/2017Q3 2017$2.38$2.46$2.55 billion$2.60 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.40$2.47$2.47 billion$2.50 billionViewN/AView Earnings Details
4/25/2017Q1 2017$2.19$2.22$2.41 billion$2.41 billionViewN/AView Earnings Details
2/16/2017Q416$2.13$2.15$2.35 billion$2.39 billionViewListenView Earnings Details
10/26/2016Q316$2.29$2.25$2.38 billion$2.40 billionViewListenView Earnings Details
7/27/2016Q216$2.30$2.31$2.33 billion$2.40 billionViewListenView Earnings Details
4/25/2016Q116$1.96$2.02$2.19 billion$2.30 billionViewListenView Earnings Details
2/18/2016Q415$1.99$1.98$2.22 billion$2.24 billionViewListenView Earnings Details
10/26/2015Q315$2.07$2.07$2.25 billion$2.30 billionViewListenView Earnings Details
7/28/2015Q215$2.03$2.09$2.22 billion$2.20 billionViewListenView Earnings Details
4/27/2015Q115$1.63$1.73$1.79 billion$1.80 billionViewListenView Earnings Details
2/20/2015Q4$1.63$1.65$1.49 billion$1.51 billionViewListenView Earnings Details
10/28/2014Q3$1.75$1.80$1.56 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$1.77$1.84$1.50 billion$1.52 billionViewN/AView Earnings Details
4/28/2014Q114$1.58$1.51$1.45 billion$1.43 billionViewListenView Earnings Details
2/7/2014Q413$1.66$1.61$1.46 billion$1.44 billionViewListenView Earnings Details
10/18/2013Q313$1.80$1.80$1.45 billion$1.46 billionViewListenView Earnings Details
7/19/2013Q2 2013$1.80$1.80$1.46 billion$1.47 billionViewListenView Earnings Details
4/19/2013Q1 2013$1.77$1.74$1.45 billion$1.44 billionViewListenView Earnings Details
2/8/2013Q4 2012$1.62$1.54$1.39 billion$1.41 billionViewListenView Earnings Details
10/18/2012$1.74$1.76ViewN/AView Earnings Details
7/19/2012$1.76$1.77ViewN/AView Earnings Details
4/19/2012$1.67$1.74ViewN/AView Earnings Details
2/10/2012$1.41$1.46ViewN/AView Earnings Details
10/20/2011$1.50$1.61ViewN/AView Earnings Details
7/21/2011$1.53$1.64ViewN/AView Earnings Details
4/21/2011$1.46$1.52ViewN/AView Earnings Details
2/10/2011$1.31$1.34ViewN/AView Earnings Details
10/21/2010Q3 2010$1.40$1.47ViewN/AView Earnings Details
7/22/2010Q2 2010$1.42$1.46ViewN/AView Earnings Details
4/21/2010Q1 2010$1.31$1.30ViewN/AView Earnings Details
2/11/2010Q4 2009$1.15$1.16ViewN/AView Earnings Details
10/22/2009Q3 2009$1.15$1.22ViewN/AView Earnings Details
7/23/2009Q2 2009$1.27$1.30ViewN/AView Earnings Details
4/23/2009Q1 2009$1.17$1.22ViewN/AView Earnings Details
2/12/2009Q4 2008$1.09$1.10ViewN/AView Earnings Details
10/23/2008Q3 2008$1.12$1.13ViewN/AView Earnings Details
7/24/2008Q2 2008$1.24$1.24ViewN/AView Earnings Details
4/24/2008Q1 2008$1.14$1.14ViewN/AView Earnings Details
2/7/2008Q4 2007$1.00$1.04ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Laboratory Corp. of America (NYSE:LH) Earnings Estimates

2018 EPS Consensus Estimate: $10.35
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$2.34$2.44$2.38
Q2 20185$2.58$2.68$2.65
Q3 20185$2.66$2.78$2.70
Q4 20185$2.56$2.68$2.62
Q1 20192$2.56$2.61$2.59
Q2 20192$2.90$2.94$2.92
Q3 20192$2.90$2.95$2.93
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Laboratory Corp. of America (NYSE:LH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Laboratory Corp. of America (NYSE LH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.90%
Institutional Ownership Percentage: 91.35%
Insider Trades by Quarter for Laboratory Corp. of America (NYSE:LH)
Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Laboratory Corp. of America (NYSE LH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/30/2017Dwight Gary GillilandDirectorSell971$153.52$149,067.923,501View SEC Filing  
9/6/2017David P KingCEOSell44,687$156.86$7,009,602.82258,753View SEC Filing  
9/5/2017David P. KingCEOSell132,713$157.06$20,843,903.78View SEC Filing  
8/25/2017F Samuel Eberts IIIInsiderSell31,500$155.22$4,889,430.0031,894View SEC Filing  
8/11/2017R Sanders WilliamsDirectorSell3,100$156.88$486,328.0010,073View SEC Filing  
8/1/2017Glenn A EisenbergCFOSell5,968$159.46$951,657.2818,122View SEC Filing  
8/1/2017Lisa J. UthgenanntInsiderSell5,000$160.00$800,000.00View SEC Filing  
5/22/2017Lance BerberianSVPSell3,613$139.84$505,241.925,789View SEC Filing  
5/9/2017Jean-Luc BelingardDirectorSell992$142.19$141,052.4832,935View SEC Filing  
3/9/2017Glenn A EisenbergCFOSell2,300$142.47$327,681.0012,556View SEC Filing  
2/24/2017Robert E Mittelstaedt JrDirectorSell5,300$142.69$756,257.0018,208View SEC Filing  
8/9/2016Lisa J UthgenanntInsiderSell1,177$140.00$164,780.003,660View SEC Filing  
8/4/2016Glenn A EisenbergCFOSell8,000$140.10$1,120,800.008,668View SEC Filing  
8/4/2016Robert E Mittelstaedt JrDirectorSell992$140.15$139,028.8012,340View SEC Filing  
6/13/2016David P KingCEOSell196,400$128.00$25,139,200.00271,210View SEC Filing  
4/27/2016Edward T DodsonInsiderSell9,392$126.42$1,187,336.642,717View SEC Filing  
3/31/2016F Samuel Eberts IIIInsiderSell4,219$116.85$492,990.1524,751View SEC Filing  
3/31/2016James T Jr. BoyleCEOSell18,132$116.81$2,117,998.9258,191View SEC Filing  
3/14/2016F Samuel Eberts IIIInsiderSell309$115.32$35,633.8818,529View SEC Filing  
3/14/2016James T Jr. BoyleCEOSell1,543$115.32$177,938.7626,410View SEC Filing  
2/25/2016Jean-Luc BelingardDirectorSell1,296$109.74$142,223.0430,722View SEC Filing  
2/16/2016F Samuel Eberts IIIInsiderSell370$103.02$38,117.4018,066View SEC Filing  
2/16/2016James T. Jr. BoyleCEOSell4,055$103.02$417,746.1023,454View SEC Filing  
2/12/2016F Samuel Eberts IIIinsiderSell405$101.67$41,176.3518,436View SEC Filing  
2/12/2016James T. Jr. BoyleCEOSell2,712$101.67$275,729.0427,509View SEC Filing  
1/8/2016F Samuel Eberts IIIInsiderSell1,215$119.05$144,645.7518,066View SEC Filing  
12/8/2015F Samuel Eberts IIIInsiderSell1,010$123.31$124,543.1019,281View SEC Filing  
11/2/2015R Sanders WilliamsDirectorSell1,850$124.30$229,955.004,176View SEC Filing  
7/1/2015David P KingCEOSell50,000$121.78$6,089,000.00View SEC Filing  
4/29/2015Jean-Luc BelingardDirectorSell1,542$123.10$189,820.20View SEC Filing  
4/23/2015James T Jr. BoyleCEOSell1,394$126.56$176,424.64View SEC Filing  
3/31/2015Mark E BrecherCMOSell20,625$126.98$2,618,962.50View SEC Filing  
3/30/2015Mark E BrecherCMOSell20,278$126.98$2,574,900.44View SEC Filing  
3/3/2015James T Jr. BoyleCOOSell1,237$123.70$153,016.90View SEC Filing  
2/13/2015James T Jr. BoyleCOOSell6,597$116.68$769,737.96View SEC Filing  
9/22/2014David P KingCEOSell65,234$104.71$6,830,652.14View SEC Filing  
9/5/2014R Sanders WilliamsDirectorSell2,000$107.95$215,900.00View SEC Filing  
8/22/2014David P KingCEOSell65,233$106.10$6,921,221.30View SEC Filing  
7/22/2014David P KingCEOSell65,233$105.55$6,885,343.15View SEC Filing  
6/9/2014James T Jr. BoyleCOOSell38,600$103.00$3,975,800.00View SEC Filing  
5/7/2014M Keith WeikelDirectorSell1,984$98.28$194,987.5213,958View SEC Filing  
3/28/2014James Jr. BoyleCOOSell2,521$98.36$247,965.5625,821View SEC Filing  
3/7/2014William HayesCFOSell23,848$94.40$2,251,251.2019,400View SEC Filing  
2/13/2014James Jr. BoyleCOOSell4,123$90.29$372,265.6728,188View SEC Filing  
2/11/2014James Jr. BoyleCOOSell1,204$91.15$109,744.6028,188View SEC Filing  
1/27/2014David KingCEOSell24,200$90.15$2,181,630.0063,699View SEC Filing  
12/24/2013David KingCEOSell25,000$90.79$2,269,750.0063,628View SEC Filing  
10/24/2013David P KingCEOSell25,000$100.91$2,522,750.00View SEC Filing  
10/17/2013James T Jr. BoyleCOOSell24,400$102.00$2,488,800.00View SEC Filing  
9/25/2013David KingCEOSell25,000$99.06$2,476,500.0063,628View SEC Filing  
8/26/2013David KingCEOSell25,000$96.60$2,415,000.0063,628View SEC Filing  
8/21/2013Robert Mittelstaedt, Jr.DirectorSell7,429$96.86$719,572.947,015View SEC Filing  
7/24/2013David P KingCEOSell25,000$97.72$2,443,000.00View SEC Filing  
6/24/2013David P KingCEOSell25,000$98.66$2,466,500.00View SEC Filing  
6/7/2013James T Jr. BoyleCOOSell63,100$99.63$6,286,653.00View SEC Filing  
5/28/2013Mark E BrecherInsiderSell16,900$100.92$1,705,548.00View SEC Filing  
5/21/2013William B HayesCFOSell127,200$100.00$12,720,000.00View SEC Filing  
5/17/2013F Samuel Eberts IIIInsiderSell10,000$98.47$984,700.00View SEC Filing  
5/10/2013James T Jr. BoyleCOOSell68,908$93.82$6,464,948.56View SEC Filing  
5/8/2013Jean-Luc BelingardDirectorSell2,536$92.88$235,543.68View SEC Filing  
4/11/2013William B HayesCFOSell22,234$95.00$2,112,230.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Laboratory Corp. of America (NYSE LH) News Headlines

Source:
DateHeadline
Laboratory Corp. of America Holdings (LH) Receives Average Rating of "Buy" from BrokeragesLaboratory Corp. of America Holdings (LH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM
LabCorp Named to FORTUNE Magazines 2018 List of ‘World’s Most Admired Companies’LabCorp Named to FORTUNE Magazine's 2018 List of ‘World’s Most Admired Companies’
finance.yahoo.com - January 19 at 5:51 PM
Laboratory Corp. of America Holdings (LH) Expected to Announce Quarterly Sales of $2.70 BillionLaboratory Corp. of America Holdings (LH) Expected to Announce Quarterly Sales of $2.70 Billion
www.americanbankingnews.com - January 18 at 8:38 AM
Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018
247wallst.com - January 16 at 5:18 PM
Laboratory Corp. of America (LH) Downgraded by ValuEngineLaboratory Corp. of America (LH) Downgraded by ValuEngine
www.americanbankingnews.com - January 10 at 1:38 PM
Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics CompaniesCovance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies
finance.yahoo.com - January 8 at 9:53 AM
Laboratory Corp. of America (LH) Earns Outperform Rating from Analysts at Evercore ISILaboratory Corp. of America (LH) Earns Outperform Rating from Analysts at Evercore ISI
www.americanbankingnews.com - January 4 at 5:04 PM
LabCorp is Scheduled to Present at the 36th Annual J.P. Morgan Healthcare ConferenceLabCorp is Scheduled to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:22 PM
Form 8-K LABORATORY CORP OF AMERI For: Jan 02 - StreetInsider.comForm 8-K LABORATORY CORP OF AMERI For: Jan 02 - StreetInsider.com
www.streetinsider.com - January 3 at 8:41 AM
Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
finance.yahoo.com - January 2 at 9:27 AM
Laboratory Corp. of America (LH) Given a $165.00 Price Target at MizuhoLaboratory Corp. of America (LH) Given a $165.00 Price Target at Mizuho
www.americanbankingnews.com - December 30 at 5:14 PM
Zacks: Analysts Expect Laboratory Corp. of America Holdings (LH) to Announce $2.37 EPSZacks: Analysts Expect Laboratory Corp. of America Holdings (LH) to Announce $2.37 EPS
www.americanbankingnews.com - December 30 at 3:14 PM
2017s top stories: LabCorp continues acquisition spree, but faces reimbursement headwinds2017's top stories: LabCorp continues acquisition spree, but faces reimbursement headwinds
finance.yahoo.com - December 28 at 1:55 PM
Laboratory Corp. of America Holdings (LH) Receives Consensus Recommendation of "Buy" from BrokeragesLaboratory Corp. of America Holdings (LH) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 26 at 4:13 AM
LabCorp (LH) at a 52-Week High: Whats Driving the Stock? - NasdaqLabCorp (LH) at a 52-Week High: What's Driving the Stock? - Nasdaq
www.nasdaq.com - December 23 at 2:20 AM
LabCorp (LH) at a 52-Week High: Whats Driving the Stock?LabCorp (LH) at a 52-Week High: What's Driving the Stock?
finance.yahoo.com - December 21 at 5:19 PM
Laboratory Corp. of Americas (LH) Buy Rating Reaffirmed at BarclaysLaboratory Corp. of America's (LH) Buy Rating Reaffirmed at Barclays
www.americanbankingnews.com - December 17 at 11:26 AM
$2.70 Billion in Sales Expected for Laboratory Corp. of America Holdings (LH) This Quarter$2.70 Billion in Sales Expected for Laboratory Corp. of America Holdings (LH) This Quarter
www.americanbankingnews.com - December 15 at 8:38 AM
Zacks: Analysts Anticipate Laboratory Corp. of America Holdings (LH) to Post $2.40 Earnings Per ShareZacks: Analysts Anticipate Laboratory Corp. of America Holdings (LH) to Post $2.40 Earnings Per Share
www.americanbankingnews.com - December 13 at 11:36 AM
ETFs with exposure to Laboratory Corp. of America Holdings : December 12, 2017ETFs with exposure to Laboratory Corp. of America Holdings : December 12, 2017
finance.yahoo.com - December 12 at 5:47 PM
LabCorp backs lawsuit challenging Medicare reimbursement ratesLabCorp backs lawsuit challenging Medicare reimbursement rates
finance.yahoo.com - December 12 at 9:57 AM
Medical lab trade group sues over U.S. reimbursement cutsMedical lab trade group sues over U.S. reimbursement cuts
finance.yahoo.com - December 11 at 5:31 PM
LabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final RuleLabCorp Supports American Clinical Laboratory Association Lawsuit on PAMA Final Rule
finance.yahoo.com - December 11 at 5:31 PM
Laboratory Corporation of America Holdings (LH) Expected to Earn FY2017 Earnings of $9.54 Per ShareLaboratory Corporation of America Holdings (LH) Expected to Earn FY2017 Earnings of $9.54 Per Share
www.americanbankingnews.com - December 1 at 10:27 AM
Laboratory Corporation of America Holdings (LH) Receives Average Recommendation of "Buy" from AnalystsLaboratory Corporation of America Holdings (LH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 6:29 AM
Laboratory Corporation of America (LH) Upgraded by ValuEngine to BuyLaboratory Corporation of America (LH) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - November 30 at 10:28 PM
LabCorps Covance Business Bounces Back on Chiltern Buyout - NasdaqLabCorp's Covance Business Bounces Back on Chiltern Buyout - Nasdaq
www.nasdaq.com - November 29 at 9:35 AM
LabCorp's Covance Business Bounces Back on Chiltern BuyoutLabCorp's Covance Business Bounces Back on Chiltern Buyout
finance.yahoo.com - November 29 at 9:35 AM
ETFs with exposure to Laboratory Corp. of America Holdings : November 27, 2017ETFs with exposure to Laboratory Corp. of America Holdings : November 27, 2017
finance.yahoo.com - November 27 at 5:09 PM
$2.70 Billion in Sales Expected for Laboratory Corporation of America Holdings (LH) This Quarter$2.70 Billion in Sales Expected for Laboratory Corporation of America Holdings (LH) This Quarter
www.americanbankingnews.com - November 27 at 6:52 AM
Jefferies Group Comments on Laboratory Corporation of America Holdings Q1 2018 Earnings (LH)Jefferies Group Comments on Laboratory Corporation of America Holdings' Q1 2018 Earnings (LH)
www.americanbankingnews.com - November 27 at 5:14 AM
Laboratory Corporation of America Holdings (LH) Stock Rating Reaffirmed by Jefferies Group LLCLaboratory Corporation of America Holdings (LH) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - November 26 at 12:08 AM
$2.40 Earnings Per Share Expected for Laboratory Corporation of America Holdings (LH) This Quarter$2.40 Earnings Per Share Expected for Laboratory Corporation of America Holdings (LH) This Quarter
www.americanbankingnews.com - November 25 at 5:08 PM
Brokers Issue Forecasts for Laboratory Corporation of America Holdings FY2017 Earnings (LH)Brokers Issue Forecasts for Laboratory Corporation of America Holdings' FY2017 Earnings (LH)
www.americanbankingnews.com - November 23 at 7:58 AM
Laboratory Corp. of America Holdings breached its 50 day moving average in a Bullish Manner : LH-US : November 22, 2017Laboratory Corp. of America Holdings breached its 50 day moving average in a Bullish Manner : LH-US : November 22, 2017
finance.yahoo.com - November 23 at 6:07 AM
William Blair Equities Analysts Increase Earnings Estimates for Laboratory Corporation of America Holdings (LH)William Blair Equities Analysts Increase Earnings Estimates for Laboratory Corporation of America Holdings (LH)
www.americanbankingnews.com - November 22 at 12:50 PM
How the finalized Medicare reimbursement rates impact LabCorp - Triad Business JournalHow the finalized Medicare reimbursement rates impact LabCorp - Triad Business Journal
www.bizjournals.com - November 22 at 1:53 AM
Reimbursement cuts on lab tests pressure US lab firm sharesReimbursement cuts on lab tests pressure US lab firm shares
finance.yahoo.com - November 21 at 2:41 AM
LabCorp Reports New Use of Agilents Cancer Diagnostic TestLabCorp Reports New Use of Agilent's Cancer Diagnostic Test
www.nasdaq.com - November 17 at 6:19 PM
LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®
finance.yahoo.com - November 17 at 6:19 PM
LabCorp firm partners with Canadian company to offer diagnostic tests for medical marijuanaLabCorp firm partners with Canadian company to offer diagnostic tests for medical marijuana
finance.yahoo.com - November 15 at 4:12 AM
LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace EqualityLabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality
finance.yahoo.com - November 13 at 1:14 PM
LabCorp Receives 2017 Partnership Award from Be The Match®LabCorp Receives 2017 Partnership Award from Be The Match®
finance.yahoo.com - November 13 at 1:14 PM
Stock Traders Buy High Volume of Call Options on Laboratory Corporation of America Holdings (LH)Stock Traders Buy High Volume of Call Options on Laboratory Corporation of America Holdings (LH)
www.americanbankingnews.com - November 12 at 1:56 AM
OmniSeq Receives CAP Accreditation and Publishes Analytical Validation PaperOmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
finance.yahoo.com - November 11 at 4:35 PM
LabCorp purchases retail division of Florida labLabCorp purchases retail division of Florida lab
www.bizjournals.com - November 8 at 6:52 PM
Laboratory Corporation Of America (LH) Presents At Credit Suisse 26th Annual Healthcare Conference - SlideshowLaboratory Corporation Of America (LH) Presents At Credit Suisse 26th Annual Healthcare Conference - Slideshow
seekingalpha.com - November 8 at 6:52 PM
ETFs with exposure to Laboratory Corp. of America Holdings : November 8, 2017ETFs with exposure to Laboratory Corp. of America Holdings : November 8, 2017
finance.yahoo.com - November 8 at 6:52 PM
Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 8 at 1:47 PM
Laboratory Corporation of America Holdings (LH) Expected to Post Quarterly Sales of $2.70 BillionLaboratory Corporation of America Holdings (LH) Expected to Post Quarterly Sales of $2.70 Billion
www.americanbankingnews.com - November 8 at 4:08 AM

SEC Filings

Laboratory Corp. of America (NYSE:LH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Laboratory Corp. of America (NYSE:LH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Laboratory Corp. of America (NYSE LH) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.